Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.
Murphy-Benenato KE, Bhagunde PR, Chen A, Davis HE, Durand-Réville TF, Ehmann DE, Galullo V, Harris JJ, Hatoum-Mokdad H, Jahić H, Kim A, Manjunatha MR, Manyak EL, Mueller J, Patey S, Quiroga O, Rooney M, Sha L, Shapiro AB, Sylvester M, Tan B, Tsai AS, Uria-Nickelsen M, Wu Y, Zambrowski M, Zhao SX. Murphy-Benenato KE, et al. Among authors: bhagunde pr. J Med Chem. 2015 Mar 12;58(5):2195-205. doi: 10.1021/jm501506f. Epub 2015 Mar 3. J Med Chem. 2015. PMID: 25658376
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Bhagunde P, Colon-Gonzalez F, Liu Y, Wu J, Xu SS, Garrett G, Jumes P, Lasseter K, Marbury T, Rizk ML, Lala M, Rhee EG, Butterton JR, Boundy K. Bhagunde P, et al. Br J Clin Pharmacol. 2020 May;86(5):944-957. doi: 10.1111/bcp.14204. Epub 2020 Jan 23. Br J Clin Pharmacol. 2020. PMID: 31856304 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Rhee EG, et al. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00280-18. doi: 10.1128/AAC.00280-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29914955 Free PMC article.
Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".
Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Rhee EG, et al. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e02197-18. doi: 10.1128/AAC.02197-18. Print 2018 Dec. Antimicrob Agents Chemother. 2018. PMID: 30478180 Free PMC article. No abstract available.
Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.
Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, Katwaru R, Si Q, Harradine P, Motyl M, Bhagunde PR, Rizk ML. Wu J, et al. Among authors: bhagunde pr. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02323-17. doi: 10.1128/AAC.02323-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29507068 Free PMC article.
Mathematical modeling to characterize the inoculum effect.
Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VH. Bhagunde P, et al. Antimicrob Agents Chemother. 2010 Nov;54(11):4739-43. doi: 10.1128/AAC.01831-09. Epub 2010 Aug 30. Antimicrob Agents Chemother. 2010. PMID: 20805390 Free PMC article.
11 results